anhydrous enol-oxaloacetate
Phase 2- Indications
- Glioblastoma Multiforme, Epilepsy
Company intelligence / Profile preview
MetVital, Inc.
San Diego, California, United Statesmetvital.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
MetVital's lead drug candidate, Anhydrous Enol-Oxaloacetate (AEO), received FDA Fast Track Designation for treatment of newly diagnosed glioblastoma multiforme. The company has a Phase 2 clinical trial for GBM patients. Their compounds have demonstrated safety and efficacy in animal models with human glioblastoma tissue implants, ALS, and Alzheimer's disease[3][5].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on MetVital, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MetVital, Inc..